Alpha Teknova, Inc. (TKNO)

In the past six months, Alpha Teknova, Inc.'s stock has been impacted by earnings reports and general market trends. The company reported its Q2 2025 earnings on August 7, 2025, with a net loss of $3.6 million, or negative $0.07 per diluted share, which was an improvement compared to the previous year, but the stock experienced a 2.53% drop after the Q2 results. On November 6, 2025, Alpha Teknova released its Q3 2025 earnings, reporting an EPS of -$0.08, exceeding analysts' expectations, but the stock declined by 2.83% after this announcement. The company also announced on February 5, 2026, that it would report its fourth-quarter and full-year 2025 financial results on February 26, 2026. Alpha Teknova's stock has seen significant fluctuations, with a 52-week range between $2.16 and $9.99. As of early February 2026, the stock was trading near its 52-week low. The company's market capitalization decreased by 39.23% in the 30 days leading up to February 4, 2026, and by 39.47% over the last 12 months. Alpha Teknova underperformed the US Life Sciences industry, which returned -6.6% over the past year, and the broader US Market, which returned 10.3% over the same period.

Publicly available information regarding specific demand seasonality for Alpha Teknova, Inc.'s products and services is not readily available. While some financial platforms indicate that seasonality analysis exists for TKNO stock to identify seasonal patterns in returns, this information typically requires a paid account to access.

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. It operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, or more broadly, Life Sciences Tools and Services. Its products include pre-poured media plates, liquid cell culture media, molecular biology reagents, lab essentials, and clinical solutions. The company serves the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions.

Alpha Teknova, Inc. operates in the United States and internationally. The company is headquartered in Hollister, California, and has expanded its operational footprint with a new state-of-the-art facility, increasing its size to over 180,000 square feet.

Alpha Teknova generally maintains a positive brand reputation among analysts. The company has received a consensus rating of "Buy" from analysts, with an average rating score based on two buy ratings, zero hold ratings, and zero sell ratings. Another assessment indicates a "Moderate Buy" consensus rating with an average score of 2.50, based on one strong buy, one buy, one hold, and one sell rating. Analysts project a median target price of $10.00 for the stock, with a high estimate of $15.00 and a low estimate of $5.00. MarketBeat also reported that Alpha Teknova scored higher than 62% of companies evaluated and ranked 401st out of 872 stocks in the medical sector.

Major owners of Alpha Teknova, Inc. include Telegraph Hill Partners IV LP, Ted Davis, Irene Davis, UBS Group AG, Balyasny Asset Management LP, Roubaix Capital LLC, J. Matthew MacKowski, Blackrock Inc, and Vanguard Group Inc. Institutional shareholders own 13.85% of Alpha Teknova, insiders own 64.05%, and retail investors own 22.09%.